NLRP3 and cancer: Instead of targeting MDSC’s directly through CD33, inhibitors that specifically target TLR signaling and their downstream effectors, IRAK and the NLRP3 inflammasome, may provide another avenue to disrupt pyroptosis-mediated cell death of HSPC’s and β-catenin-induced proliferation of cancer cells.